SEC Comment Letter 0000000000-24-007133 to AGIOS PHARMACEUTICALS, INC. (AGIO) (CIK 0001439222) (AGIO)
AGIOS PHARMACEUTICALS, INC. (AGIO) (CIK 0001439222)
Date: June 24, 2024 · CIK: 0001439222 · Accession: 0000000000-24-007133
AI Filing Summary & Sentiment
File numbers found in text: 001-36014
Letter
United States securities and exchange commission logo June 24, 2024 Cecilia Jones Chief Financial Officer AGIOS PHARMACEUTICALS, INC. 88 Sidney Street Cambridge, MA 02139 Re:AGIOS PHARMACEUTICALS, INC. Form 10-K for Fiscal Year Ended December 31, 2023 Filed February 15, 2024 File No. 001-36014 Dear Cecilia Jones: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
June 24, 2024
Cecilia Jones
Chief Financial Officer
AGIOS PHARMACEUTICALS, INC.
88 Sidney Street
Cambridge, MA 02139
Re:AGIOS PHARMACEUTICALS, INC.
Form 10-K for Fiscal Year Ended December 31, 2023
Filed February 15, 2024
File No. 001-36014
Dear Cecilia Jones:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences